Free Trial

Matinas Biopharma (MTNB) Competitors

Matinas Biopharma logo
$0.79 +0.02 (+2.21%)
Closing price 03:55 PM Eastern
Extended Trading
$0.76 -0.02 (-2.80%)
As of 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MTNB vs. CLDI, RLYB, NKGN, HOTH, NXTC, IMNN, NERV, BCTX, BGXX, and CLRB

Should you be buying Matinas Biopharma stock or one of its competitors? The main competitors of Matinas Biopharma include Calidi Biotherapeutics (CLDI), Rallybio (RLYB), NKGen Biotech (NKGN), Hoth Therapeutics (HOTH), NextCure (NXTC), Imunon (IMNN), Minerva Neurosciences (NERV), BriaCell Therapeutics (BCTX), Bright Green (BGXX), and Cellectar Biosciences (CLRB). These companies are all part of the "pharmaceutical products" industry.

Matinas Biopharma vs.

Calidi Biotherapeutics (NYSE:CLDI) and Matinas Biopharma (NYSE:MTNB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, community ranking, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

Calidi Biotherapeutics has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Comparatively, Matinas Biopharma has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500.

Calidi Biotherapeutics' return on equity of 0.00% beat Matinas Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Calidi BiotherapeuticsN/A N/A -344.45%
Matinas Biopharma N/A -123.06%-94.28%

Calidi Biotherapeutics and Matinas Biopharma both received 0 outperform votes by MarketBeat users.

CompanyUnderperformOutperform
Calidi BiotherapeuticsN/AN/A
Matinas BiopharmaN/AN/A

Matinas Biopharma has higher revenue and earnings than Calidi Biotherapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calidi Biotherapeutics$50K231.73-$29.22MN/AN/A
Matinas Biopharma$1.10M3.76-$22.94M-$3.86-0.21

In the previous week, Calidi Biotherapeutics had 3 more articles in the media than Matinas Biopharma. MarketBeat recorded 3 mentions for Calidi Biotherapeutics and 0 mentions for Matinas Biopharma. Calidi Biotherapeutics' average media sentiment score of 0.23 beat Matinas Biopharma's score of 0.00 indicating that Calidi Biotherapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Calidi Biotherapeutics Neutral
Matinas Biopharma Neutral

Calidi Biotherapeutics presently has a consensus target price of $10.00, indicating a potential upside of 2,357.00%. Given Calidi Biotherapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Calidi Biotherapeutics is more favorable than Matinas Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Calidi Biotherapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Matinas Biopharma
0 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

12.5% of Calidi Biotherapeutics shares are owned by institutional investors. Comparatively, 11.8% of Matinas Biopharma shares are owned by institutional investors. 24.3% of Calidi Biotherapeutics shares are owned by company insiders. Comparatively, 6.0% of Matinas Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Calidi Biotherapeutics beats Matinas Biopharma on 10 of the 13 factors compared between the two stocks.

Get Matinas Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MTNB vs. The Competition

MetricMatinas BiopharmaPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$4.14M$6.51B$5.34B$19.36B
Dividend YieldN/A2.64%5.21%3.83%
P/E Ratio-0.179.2026.9034.63
Price / Sales3.76258.37389.4835.13
Price / CashN/A65.8538.2517.51
Price / Book0.186.466.784.70
Net Income-$22.94M$144.21M$3.23B$1.02B
7 Day Performance5.71%2.66%2.02%-1.53%
1 Month Performance35.69%4.83%10.97%7.75%
1 Year PerformanceN/A-2.54%17.38%4.40%

Matinas Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MTNB
Matinas Biopharma
N/A$0.79
+2.2%
N/AN/A$4.00M$1.10M-0.1630Gap Down
CLDI
Calidi Biotherapeutics
1.9362 of 5 stars
$0.44
-3.3%
$15.00
+3,279.9%
N/A$12.63M$50,000.000.0038
RLYB
Rallybio
1.8862 of 5 stars
$0.30
+2.7%
$10.00
+3,223.4%
-79.8%$12.52M$636,000.00-0.1940
NKGN
NKGen Biotech
N/A$0.28
+61.4%
N/A-85.8%$12.41M$80,000.00-0.05N/APositive News
Gap Up
HOTH
Hoth Therapeutics
2.7297 of 5 stars
$0.93
-2.5%
$4.00
+330.5%
-29.5%$12.24MN/A-0.704Analyst Downgrade
NXTC
NextCure
3.9506 of 5 stars
$0.43
-2.6%
$3.50
+705.9%
-69.7%$12.18MN/A-0.2190Positive News
Gap Down
IMNN
Imunon
1.5723 of 5 stars
$0.82
+2.0%
$21.50
+2,535.1%
-72.3%$11.93M$500,000.00-0.4330News Coverage
Analyst Forecast
Gap Up
NERV
Minerva Neurosciences
2.9216 of 5 stars
$1.66
+2.9%
$5.00
+201.9%
-41.1%$11.58MN/A-3.769News Coverage
Analyst Forecast
Gap Up
BCTX
BriaCell Therapeutics
1.2956 of 5 stars
$3.12
+0.3%
$32.00
+925.6%
-84.5%$11.57MN/A-0.238
BGXX
Bright Green
N/AN/AN/AN/A$11.47MN/A-1.002News Coverage
Gap Down
CLRB
Cellectar Biosciences
2.3173 of 5 stars
$0.26
+6.8%
$12.50
+4,633.1%
-92.3%$11.40MN/A-0.1510Analyst Forecast

Related Companies and Tools


This page (NYSE:MTNB) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners